Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923111 | 1.00 | FGFR1 (0.41) | FGFR1KDRHDAC6FGFR2GPR35 | |
| SCHEMBL7954698 | 0.95 | FGFR1 (0.41) | FGFR1KDRHDAC6FGFR2EPHB3 | |
| SCHEMBL3233985 | 0.91 | RAB9A (0.42) | FGFR1KDRFGFR2EPHB3FGFR4 | |
| SCHEMBL3242268 | 0.89 | FGFR4 (0.42) | FGFR1KDRHDAC6FGFR2GPR35 | |
| SCHEMBL13099651 | 0.88 | CDK1 (0.40) | EPHB3KMT2AMEN1CDK2 | |
| SCHEMBL3234709 | 0.88 | FGFR4 (0.46) | EPHB3FGFR4KMT2AMEN1NPC1 | |
| SCHEMBL8031078 | 0.87 | FGFR4 (0.41) | FGFR1KDREPHB3FGFR4CDK2 | |
| SCHEMBL24624641 | 0.87 | FGFR1 (0.38) | FGFR1HDAC6FGFR2KMT2ADYRK1A | |
| SCHEMBL8052018 | 0.85 | FGFR4 (0.48) | EPHB3FGFR4 | |
| SCHEMBL13099704 | 0.85 | CDK2 (0.42) | FGFR1HDAC6FGFR2EPHB3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340415-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | AMNIOTICS AB (SE) | 2023-10-26 | — | — | US | claimed |
| US-11542473-B2 | Methods and compositions for generating hematopoietic cells | AMNIOTICS AB (SE) | 2023-01-03 | — | — | US | claimed |
| US-20200048609-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | LONGBOAT AMNIOTICS AB (SE) | 2020-02-13 | — | — | US | claimed |
| US-20180289731-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP, LLC | 2018-10-11 | — | — | US | claimed |
| WO-2018073615-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | LONGBOAT EXPLORERS AB (SE) | 2018-04-26 | — | — | WO | claimed |
| WO-2016176675-A2 | PATIENT TREATMENT VIA TERATOGENIC PHARMACEUTICAL COMPOUNDS | NANT HOLDINGS IP, LLC (US) | 2016-11-03 | — | — | WO | claimed |
| US-20240216409-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP, LLC (US) | 2024-07-04 | — | — | US | disclosed |
| US-12016872-B2 | Patient treatment via teratogenic pharmaceutical compounds | NANT HOLDINGS IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230340415-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | AMNIOTICS AB (SE) | 2023-10-26 | — | — | US | disclosed |
| US-11542473-B2 | Methods and compositions for generating hematopoietic cells | AMNIOTICS AB (SE) | 2023-01-03 | — | — | US | disclosed |
| US-11000536-B2 | Patient treatment via teratogenic pharmaceutical compounds | NANT HOLDINGS IP, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200405738-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP LLC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200048609-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC CELLS | LONGBOAT AMNIOTICS AB (SE) | 2020-02-13 | — | — | US | disclosed |
| US-20180289731-A1 | Patient Treatment Via Teratogenic Pharmaceutical Compounds | NANT HOLDINGS IP, LLC | 2018-10-11 | — | — | US | disclosed |
| WO-2016176675-A2 | PATIENT TREATMENT VIA TERATOGENIC PHARMACEUTICAL COMPOUNDS | NANT HOLDINGS IP, LLC (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | FGFR1 533/4885KDR 2436/4885HDAC6 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.